The price of GE HealthCare Technologies Inc. (NASDAQ:GEHC) shares last traded on Wall Street rose 0.95% to $82.63.
Based on available information, 10 analysts follow GE HealthCare Technologies Inc. (NASDAQ:GEHC). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $97.00 and a low of $76.00, we find $92.00. Given the previous closing price of $81.85, this indicates a potential upside of 12.4 percent. GEHC stock price is now 4.37% away from the 50-day moving average and 10.55% away from the 200-day moving average. The market capitalization of the company currently stands at $37.21B.
Among analysts, 3 rate the stock a hold while 5 rate it a buy. Brokers who have rated the stock have averaged $89.50 as their price target over the next twelve months.
With the price target of $76, Morgan Stanley recently initiated with Equal-Weight rating for GE HealthCare Technologies Inc. (NASDAQ: GEHC).
In other news, Rott Roland, CEO, Ultrasound sold 2,473 shares of the company’s stock on Jun 08. The stock was sold for $191,336 at an average price of $77.37. Upon completion of the transaction, the CEO, Ultrasound now directly owns 22,335 shares in the company, valued at $1.85 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 14, CEO, Imaging Makela Jan sold 70,629 shares of the business’s stock. A total of $5,487,379 was realized by selling the stock at an average price of $77.69. This leaves the insider owning 63,796 shares of the company worth $5.27 million. Insiders disposed of 391,218,211 shares of company stock worth roughly $32.33 billion over the past 1 year. A total of 0.05% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GEHC stock. A new stake in GE HealthCare Technologies Inc. shares was purchased by NEWPORT TRUST CO during the first quarter worth $453,633,000. SOUND SHORE MANAGEMENT INC /CT/ invested $83,050,000 in shares of GEHC during the first quarter. In the first quarter, JENNISON ASSOCIATES LLC acquired a new stake in GE HealthCare Technologies Inc. valued at approximately $42,044,000. BOWEN HANES & CO INC acquired a new stake in GEHC for approximately $34,397,000. BRAUN STACEY ASSOCIATES INC purchased a new stake in GEHC valued at around $33,991,000 in the second quarter. In total, there are 507 active investors with 56.98% ownership of the company’s stock.
A candlestick chart of GE HealthCare Technologies Inc. (NASDAQ: GEHC) showed a price of $82.08 on Friday morning. During the past 12 months, GE HealthCare Technologies Inc. has had a low of $53.00 and a high of $87.83. As of last week, the company has a debt-to-equity ratio of 1.53, a current ratio of 1.20, and a quick ratio of 0.90. The fifty day moving average price for GEHC is $79.29 and a two-hundred day moving average price translates $74.80 for the stock.
The latest earnings results from GE HealthCare Technologies Inc. (NASDAQ: GEHC) was released for Mar, 2023. The net profit margin was 10.20% and return on equity was 15.20% for GEHC. For the current quarter, analysts expect GEHC to generate $4.79B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 08/15/2023. Investors who held shares on 07/21/2023 were paid a $0.03 dividend. On an annualized basis, this represents a $0.12 dividend and a 0.15% percent yield. There was an ex-dividend date of 07/20/2023 for this dividend.
GE HealthCare Technologies Inc.(GEHC) Company Profile
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women’s health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
